57 related articles for article (PubMed ID: 38475661)
1. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
Cancer Lett; 2024 May; 594():216984. PubMed ID: 38797230
[TBL] [Abstract][Full Text] [Related]
2. Unlocking Precision Medicine: Liquid Biopsy Advancements in Renal Cancer Detection and Monitoring.
Crocetto F; Falcone A; Mirto BF; Sicignano E; Pagano G; Dinacci F; Varriale D; Machiella F; Giampaglia G; Calogero A; Varlese F; Balsamo R; Trama F; Sciarra A; Del Giudice F; Busetto GM; Ferro M; Lucarelli G; Lasorsa F; Imbimbo C; Barone B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612677
[TBL] [Abstract][Full Text] [Related]
3. Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors.
Veccia A; Falagario U; Martini A; Marchioni M; Antonelli A; Simeone C; Cormio L; Capitanio U; Mir MC; Derweesh I; Van Poppel H; Porpiglia F; Autorino R
Eur Urol Focus; 2021 May; 7(3):574-581. PubMed ID: 32571744
[TBL] [Abstract][Full Text] [Related]
4. Robotic Partial
Stout TE; Gellhaus PT; Tracy CR; Steinberg RL
J Endourol; 2023 Sep; 37(9):978-985. PubMed ID: 37358403
[No Abstract] [Full Text] [Related]
5. ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy.
Park JS; Kim H; Jang WS; Kim J; Ham WS; Lee ST
Cancer Sci; 2024 May; 115(5):1680-1687. PubMed ID: 38475661
[TBL] [Abstract][Full Text] [Related]
6. A novel nomogram can predict pathological T3a upstaged from clinical T1a in localized renal cell carcinoma.
Cao C; Kang X; Shang B; Shou J; Shi H; Jiang W; Xie R; Zhang J; Zhang L; Zheng S; Bi X; Li C; Ma J
Int Braz J Urol; 2022; 48(5):784-794. PubMed ID: 35838503
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria.
Hamilton ZA; Capitanio U; Pruthi D; Ghali F; Larcher A; Patel DN; Eldefrawy A; Patel S; Cotta BH; Bradshaw AW; Meagher MF; Miller NS; Carenzi C; Wan F; Liss MA; McGregor T; Montorsi F; Derweesh IH
Urology; 2020 Apr; 138():60-68. PubMed ID: 31836465
[TBL] [Abstract][Full Text] [Related]
8. Prognostic features of upstaged pT3a renal tumors with fat invasion after robot-assisted partial nephrectomy: is it time for a new subclassification?
Di Maida F; Campi R; Grosso AA; Lambertini L; Cadenar A; Giudici S; Pecoraro A; Mari A; Serni S; Minervini A;
Eur J Surg Oncol; 2023 Apr; 49(4):862-867. PubMed ID: 36528511
[TBL] [Abstract][Full Text] [Related]
9. Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma.
Salmasi A; Faiena I; Lenis AT; Pooli A; Johnson DC; Drakaki A; Gollapudi K; Blumberg J; Pantuck AJ; Chamie K
Urol Oncol; 2018 Dec; 36(12):527.e13-527.e19. PubMed ID: 30228094
[TBL] [Abstract][Full Text] [Related]
10. The preoperative predictive factors for pathological T3a upstaging and positive surgical margin of clinical T1 renal cell carcinoma.
Çil G; Yilmaz M; Sahin Y; Ulus I; Canıtez IO; Kandıralı IE
Actas Urol Esp (Engl Ed); 2024 May; 48(4):311-318. PubMed ID: 38369290
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Characteristics of Circulating Tumor DNA in Pt1a Clear Cell Renal Cell Carcinoma: A Pilot Study.
Kim H; Park JS; Choi Z; Min S; Park J; Shin S; Choi JR; Lee ST; Ham WS
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444416
[TBL] [Abstract][Full Text] [Related]
12. A morphology-based nephrometry score to predict pathological upstaging to T3 renal cell carcinoma.
Zhang W; Shi H; Yang Y; Xiao C; Nian X; Gao Y; Liu W; Pang Q; Shi X
Transl Androl Urol; 2022 Dec; 11(12):1645-1654. PubMed ID: 36632158
[TBL] [Abstract][Full Text] [Related]
13. Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.
Lee KS; Seo J; Lee CK; Shin S; Choi Z; Min S; Yang JH; Kwon WS; Yun W; Park MR; Choi JR; Chung HC; Lee ST; Rha SY
Clin Chem; 2022 Dec; 68(12):1519-1528. PubMed ID: 36306340
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma.
Bootsma M; McKay RR; Emamekhoo H; Bade RM; Schehr JL; Mannino MC; Singh A; Wolfe SK; Schultz ZD; Sperger J; Xie W; Signoretti S; Kyriakopoulos CE; Kosoff D; Abel EJ; Helzer KT; Rydzewski N; Bakhtiar H; Shi Y; Blitzer G; Bassetti M; Floberg J; Yu M; Sethakorn N; Sharifi M; Harari PM; Choueiri TK; Lang JM; Zhao SG
J Clin Oncol; 2022 Nov; 40(31):3633-3641. PubMed ID: 35617646
[TBL] [Abstract][Full Text] [Related]
15. Robotic-assisted tumor enucleation versus standard margin partial nephrectomy: Perioperative, renal functional, and oncologic outcomes for low and intermediate complexity renal masses.
Patel HD; Koehne EL; Gali K; Lanzotti NJ; Rac G; Desai S; Pahouja G; Quek ML; Gupta GN
Urol Oncol; 2022 Jul; 40(7):347.e9-347.e16. PubMed ID: 35551863
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
